Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 41, Issue -, Pages 47-54Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.05.014
Keywords
-
Categories
Funding
- Wellcome Trust
- Medical Research Council
- Department for International Development
- European Union Seventh Framework Programme
- Oxford NIHR Biomedical Research Centre
- MRC [MC_PC_13073, MR/M007693/1] Funding Source: UKRI
- Medical Research Council [MR/M007693/1, MC_PC_13073] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0509-10233, NF-SI-0514-10158] Funding Source: researchfish
- Wellcome Trust [104750/Z/14/Z] Funding Source: researchfish
Ask authors/readers for more resources
Viral vectors are the vaccine platform of choice for many pathogens that have thwarted efforts towards control using conventional vaccine approaches. Although the STEP trial encumbered development of recombinant human adenovirus vectors only a few years ago, replication-deficient simian adenoviruses have since emerged as a crucial component of clinically effective prime-boost regimens. The vectors discussed here elicit functionally relevant cellular and humoral immune responses, at extremes of age and in diverse populations. The recent Ebola virus outbreak highlighted the utility of viral vectored vaccines in facilitating a rapid response to public health emergencies. Meanwhile, technological advances in manufacturing to support scale-up of viral vectored vaccines have helped to consolidate their position as a leading approach to tackling 'old' and emerging infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available